BRPI0924061B8 - composicão farmacêutica compreendendo uma proteína endorepellin - Google Patents
composicão farmacêutica compreendendo uma proteína endorepellinInfo
- Publication number
- BRPI0924061B8 BRPI0924061B8 BRPI0924061A BRPI0924061A BRPI0924061B8 BR PI0924061 B8 BRPI0924061 B8 BR PI0924061B8 BR PI0924061 A BRPI0924061 A BR PI0924061A BR PI0924061 A BRPI0924061 A BR PI0924061A BR PI0924061 B8 BRPI0924061 B8 BR PI0924061B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- endorepellin protein
- endorepellin
- protein
- angiogenesis
- Prior art date
Links
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 abstract 3
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108010049224 perlecan Proteins 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
intensificadores de angiogênese gerada por acidente vascular cerebral e usos dos mesmos. a presente invenção refere-se a métodos de estimular ou intensificar angiogênese em um paciente compreendendo, administrar a referido paciente uma quantidade terapeuticamente efetiva de uma proteína endorepellin, em que referida proteína endorepellin tem uma sequência de aminoácido de domínio v de perlecan ou fragmentos ou derivados, análogos dos mesmos; e estimular ou intensificar geração de vasos sanguíneos. a presente invenção é direcionada a composições para intensificar angiogênese.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20406408P | 2008-12-31 | 2008-12-31 | |
| US61/204,064 | 2008-12-31 | ||
| PCT/US2009/006758 WO2010077364A2 (en) | 2008-12-31 | 2009-12-31 | Stroke-generated angiogenesis enhancers and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0924061A2 BRPI0924061A2 (pt) | 2015-07-07 |
| BRPI0924061B1 BRPI0924061B1 (pt) | 2020-11-24 |
| BRPI0924061B8 true BRPI0924061B8 (pt) | 2021-05-25 |
Family
ID=42174116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0924061A BRPI0924061B8 (pt) | 2008-12-31 | 2009-12-31 | composicão farmacêutica compreendendo uma proteína endorepellin |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8466105B2 (pt) |
| EP (1) | EP2373328B1 (pt) |
| JP (1) | JP5591825B2 (pt) |
| KR (1) | KR101746749B1 (pt) |
| CN (2) | CN104208659A (pt) |
| AU (1) | AU2009333815B2 (pt) |
| BR (1) | BRPI0924061B8 (pt) |
| CA (1) | CA2748811C (pt) |
| ES (1) | ES2524366T3 (pt) |
| MX (1) | MX2011007108A (pt) |
| RU (1) | RU2011131772A (pt) |
| WO (1) | WO2010077364A2 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011085136A2 (en) | 2010-01-06 | 2011-07-14 | Elan Pharmaceuticals, Inc. | Use of perlecan domain v in treating amyloidogenic disease |
| CA2804154C (en) | 2010-07-01 | 2021-06-01 | The Texas A&M University System | Perlecan domain v protects, repairs and restores ischemic brain stroke injury and motor function |
| US11413326B2 (en) | 2017-12-13 | 2022-08-16 | University Of Kentucky Research Foundation | Compositions and methods for enhancing neuro-repair |
| CN108715833B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种负载血小板裂解液的微球制备方法 |
| IL300114A (en) * | 2020-07-24 | 2023-03-01 | Stream Biomedical Inc | Use of PERLECAN and its fractions to reduce the risk of death in stroke patients |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6821947B2 (en) * | 2001-12-04 | 2004-11-23 | Thomas Jefferson University | Endorepellin: methods and compositions for inhibiting angiogenesis |
-
2009
- 2009-12-31 US US12/655,503 patent/US8466105B2/en active Active
- 2009-12-31 WO PCT/US2009/006758 patent/WO2010077364A2/en not_active Ceased
- 2009-12-31 ES ES09798982.6T patent/ES2524366T3/es active Active
- 2009-12-31 JP JP2011544419A patent/JP5591825B2/ja active Active
- 2009-12-31 CN CN201410468572.2A patent/CN104208659A/zh active Pending
- 2009-12-31 MX MX2011007108A patent/MX2011007108A/es active IP Right Grant
- 2009-12-31 KR KR1020117017783A patent/KR101746749B1/ko active Active
- 2009-12-31 CN CN2009801575925A patent/CN102355905A/zh active Pending
- 2009-12-31 EP EP09798982.6A patent/EP2373328B1/en active Active
- 2009-12-31 AU AU2009333815A patent/AU2009333815B2/en active Active
- 2009-12-31 CA CA2748811A patent/CA2748811C/en active Active
- 2009-12-31 BR BRPI0924061A patent/BRPI0924061B8/pt active IP Right Grant
- 2009-12-31 RU RU2011131772/15A patent/RU2011131772A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8466105B2 (en) | 2013-06-18 |
| EP2373328B1 (en) | 2014-08-20 |
| ES2524366T3 (es) | 2014-12-05 |
| AU2009333815B2 (en) | 2016-02-18 |
| AU2009333815A1 (en) | 2011-08-11 |
| MX2011007108A (es) | 2011-09-28 |
| RU2011131772A (ru) | 2013-02-10 |
| JP5591825B2 (ja) | 2014-09-17 |
| US20100168025A1 (en) | 2010-07-01 |
| WO2010077364A2 (en) | 2010-07-08 |
| CA2748811C (en) | 2019-07-16 |
| BRPI0924061B1 (pt) | 2020-11-24 |
| BRPI0924061A2 (pt) | 2015-07-07 |
| CN104208659A (zh) | 2014-12-17 |
| KR20110127131A (ko) | 2011-11-24 |
| EP2373328A2 (en) | 2011-10-12 |
| CN102355905A (zh) | 2012-02-15 |
| KR101746749B1 (ko) | 2017-06-13 |
| JP2012514036A (ja) | 2012-06-21 |
| WO2010077364A3 (en) | 2010-10-21 |
| CA2748811A1 (en) | 2010-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020539A2 (pt) | Compostos específicos para proteína s de coronavírus e usos dos mesmos | |
| BR112013027674A2 (pt) | "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha". | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| BR112012009376A2 (pt) | composição farmacêutica, forma de dosagem farmacêutica, processo para a sua preparação, métodos de tratamento e seu uso | |
| BRPI0814097A8 (pt) | Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado | |
| BR112012014180A2 (pt) | composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio. | |
| Bae et al. | Role of histidine/histamine in carnosine-induced neuroprotection during ischemic brain damage | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112012024934A2 (pt) | sistemas de ablação de transgene induzida farmacologicamente | |
| BRPI0609393B8 (pt) | usos de um composto 11-desóxi-prostaglandina | |
| BR112013026706A2 (pt) | composições nutricionais compreendendo ácido alfa-hidroxi-isocaproico | |
| BR112014011645A2 (pt) | combinação de um inibidor da fosfoinositida 3-quinase e um modulador da quinase janus 2-transdutor de sinal e ativador da via de transcrição 5 | |
| BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
| BR112013026114A2 (pt) | composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas | |
| MX2011008448A (es) | Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia. | |
| BR112014012056A8 (pt) | compostos farmacêuticos | |
| BR112015000136A2 (pt) | fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento | |
| BR112013027034A2 (pt) | "composições farmacêuticas compreendendo enzimas digestivas e seu uso". | |
| BR112014003071A2 (pt) | tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical | |
| BR112013031652A2 (pt) | métodos de tratamento para doenças retinais | |
| BR112013020586A2 (pt) | Uso de células derivadas de tecido do cordão umbilical | |
| BR112015001313A2 (pt) | composições de vacina | |
| BRPI0922789A2 (pt) | peptídeo de ligação de albumina intermediador para reconhecimento de doença | |
| BR102013003570A8 (pt) | Composições de plasma rico em plaquetas | |
| BRPI0905687A8 (pt) | composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/12/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |